Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Repare Therapeutics Inc
(NQ:
RPTX
)
3.520
-0.110 (-3.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Repare Therapeutics Inc
< Previous
1
2
3
Next >
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
June 08, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
June 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
June 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
June 02, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
April 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
NASDAQ: RPTX Investor Alert: Investigation over Potential Wrongdoing at Repare Therapeutics Inc.
April 28, 2023
San Diego, CA -- (SBWIRE) -- 04/28/2023 -- Certain directors of Repare Therapeutics Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
April 18, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
March 14, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Inc. (NASDAQ:RPTX) Investor Investigation over Possible Violations of Securities Laws
February 22, 2023
San Diego, CA -- (SBWIRE) -- 02/22/2023 -- An investigation shares over potential securities laws violations by Repare Therapeutics Inc.
Via
SBWire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation
February 08, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
January 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 19, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
September 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
June 01, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
May 09, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
April 20, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
April 11, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
April 08, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
February 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
January 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
January 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.